Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06443775 · ClinicalTrials.gov registry record
An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
A clinical trial, sponsored by AbbVie.
- Completed
- Registry status
- 47
- Enrollment target
NCT06443775 is a clinical trial that has completed, run by AbbVie. The registered enrollment target is 47 participants.
The verdict
NCT06443775 has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) in adult participants with dry eye symptoms and who are high digital device users. NGE-UD is an over-the-counter (OTC) monograph drug indicated for the temporary relief of symptoms of eye dryness. Participants will administer 1 drop of NGE-UD on Day 1 for the acute phase of the study, after Day 1 participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15. Around 50 adult participants will be enrolled at one site in the United States. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site as per standard of care.
Interventions
- DRUG Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2024-10-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06443775
The ClinicalTrials.gov registry entry for NCT06443775 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) is the first listed.
NCT06443775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06443775 about?
NCT06443775 is a clinical study titled "An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)". Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) in adult particip...
What is the current status of trial NCT06443775?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2024-06-17. Estimated completion is 2024-10-14.
What interventions are being tested in trial NCT06443775?
The interventions under investigation include: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) (DRUG).
Who is sponsoring clinical trial NCT06443775?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.